Table 2.

Ongoing and Planned Clinical Trials of Topical Microbicide Candidates (January 2012)

Phase	Trial name	Candidate(s)	Mechanism of action	Location	Population
IIIb	CAPRISA 008	Tenofovir gel	Replication inhibitor	South Africa	700 women planned
III	MTN020	Dapivirine vaginal ring	Replication inhibitor	Malawi, South Africa, Uganda, Zambia, Zimbabwe	3476 women planned
	IPM 027	Dapivirine vaginal ring	Replication inhibitor	Kenya, Malawi, South Africa, Rwanda	1650 women planned
	FACTS 001[49]	Tenofovir gel	Replication inhibitor	South Africa	2200 women
IIb	VOICE[46]	Tenofovir gel; Oral TDF/FTC*	Replication inhibitor	Malawi, South Africa, Uganda, Zimbabwe	5,000 heterosexual women
II	MTN 017	Reformulated tenofovir gel for rectal use	Replication inhibitor	Peru, South Africa, Thailand, United States	216 men who have sex with men planned
I/II	IPM 015[53]	Dapivirine vaginal ring	Replication inhibitor	South Africa, Kenya, Malawi, Rwanda, Tanzania	280 women
	IPM 014A[54]	Dapivirine vaginal gel	Replication inhibitor	Kenya, Malawi, Rwanda, South Africa	320 women
	IPM 014B[54]	Dapivirine vaginal gel	Replication inhibitor	South Africa	320 women
	IPM 020[55]	Dapivirine vaginal gel	Replication inhibitor	United States	180 women
I	AF 020[51]	Amphora™/ ACIDFORM™ gel	Barrier / Maintenance of normal vaginal defences	United States	36 women
	MTN 012 / IPM 010 [56]	Dipivarine vaginal gel	Replication inhibitor	United States	48 men
	MTN 013 / IPM 026 [57]	Dapivirine and miraviroc vaginal ring	Replication inhibitor	United States	48 women
	MTN 007[58]	Reformulated Tenofovir gel for rectal use	Replication inhibitor	United States	63 women and men
	Project gel[59]	Tenofovir gel	Replication inhibitor	US, Puerto Rico	240 MSM

^*Note the tenofovir gel, and oral TDF arms in this study were prematurely halted for futility. The FTC arm is continuing

Adapted from the Global Advocacy for HIV prevention tables on ongoing and planned clinical trials – http://www.avac.org/ht/d/sp/i/3512/pid/3512